<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563147</url>
  </required_header>
  <id_info>
    <org_study_id>AV-951-07-102</org_study_id>
    <nct_id>NCT00563147</nct_id>
  </id_info>
  <brief_title>A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and tolerability of tivozanib (AV-951) and&#xD;
      Torisel™ given in combination for renal cell cancer. The study will also assess the effects&#xD;
      of the combination of tivozanib (AV-951) and Torisel™ on the tumor. Tivozanib (AV-951) is a&#xD;
      VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking&#xD;
      blood flow to the tumor. Temsirolimus is an mTOR inhibitor which is approved for the&#xD;
      treatment of advanced renal cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b, open-label, dose-finding study of tivozanib (AV-951) in combination with&#xD;
      temsirolimus to include approximately 36 subjects with metastatic renal cell carcinoma&#xD;
      (mRCC). This study is designed to evaluate the safety, tolerability, dose-limiting toxicities&#xD;
      (DLT), maximum tolerated dose (MTD), pharmacokinetic, pharmacogenomic, and antineoplastic&#xD;
      activity of tivozanib (AV-951) when administered in combination with temsirolimus. Tivozanib&#xD;
      (AV-951) will be administered once daily for 3 weeks beginning on Day 1 of Cycle 1, followed&#xD;
      by 1 week off (1 cycle = 4 weeks). Temsirolimus will be administered intravenously once&#xD;
      weekly starting on Day 8 of Cycle 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of tivozanib (AV-951) when given in combination with temsirolimus</measure>
    <time_frame>4 weeks (1 cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic profile of tivozanib (AV-951) and temsirolimus when administered in combination</measure>
    <time_frame>8 weeks (2 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the antineoplastic activity of tivozanib (AV-951) and temsirolimus when administered in combination</measure>
    <time_frame>8 weeks (2 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of tivozanib (AV-951) and temsirolimus on global and targeted gene expression patterns</measure>
    <time_frame>8 weeks (2 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) of tivozanib (AV-951) when administered in combination with temsirolimus</measure>
    <time_frame>4 weeks (1 cycle)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tivozanib (AV-951) plus temsirolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tivozanib (AV-951) plus temsirolimus</intervention_name>
    <description>ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Torisel (temsirolimus)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18-year-old males or females&#xD;
&#xD;
          -  Histologically confirmed renal cell carcinoma with a clear cell component&#xD;
&#xD;
          -  Documented progressive disease&#xD;
&#xD;
          -  Measurable disease by RECIST criteria&#xD;
&#xD;
          -  No more than 1 prior VEGF receptor targeted therapy; no prior treatment with&#xD;
             temsirolimus or other drugs targeting the mTOR pathway&#xD;
&#xD;
          -  Karnofsky performance status &gt; 70%; life expectancy ≥ 3 months&#xD;
&#xD;
          -  Ability to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to temsirolimus or its metabolites (including sirolimus),&#xD;
             polysorbate 80, or to any other component of the temsirolimus formulation&#xD;
&#xD;
          -  Primary CNS malignancies; active CNS metastases&#xD;
&#xD;
          -  Hematologic malignancies (including leukemia in any form, lymphoma, and multiple&#xD;
             myeloma)&#xD;
&#xD;
          -  Any of the following hematologic abnormalities:&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 g/dL&#xD;
&#xD;
               -  ANC &lt; 1500 per mm3&#xD;
&#xD;
               -  Platelet count &lt; 100,000 per mm3&#xD;
&#xD;
          -  Any of the following serum chemistry abnormalities:&#xD;
&#xD;
               -  Fasting serum cholesterol &gt; 350 mg/dL&#xD;
&#xD;
               -  Fasting triglycerides &gt; 400 mg/dL&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 × ULN&#xD;
&#xD;
               -  AST or ALT &gt; 2.5 × ULN (or &gt; 5 x ULN in subjects with liver metastasis)&#xD;
&#xD;
               -  Serum albumin &lt; 3.0 g/dL&#xD;
&#xD;
               -  Creatine &gt; 1.5 × ULN (or calculated CLCR &lt;50 mL/min/1.73 m2)&#xD;
&#xD;
               -  Proteinuria &gt; 2.5 g/24 hours or 3+ with urine dipstick&#xD;
&#xD;
          -  Significant cardiovascular disease, including:&#xD;
&#xD;
               -  Active clinically symptomatic left ventricular failure&#xD;
&#xD;
               -  Active hypertension (diastolic blood pressure &gt; 100 mmHg). Subjects with a&#xD;
                  history of hypertension must have been on stable doses of anti-hypertensive drugs&#xD;
                  for ≥ 4 weeks&#xD;
&#xD;
               -  Uncontrolled hypertension: Blood pressure &gt;140/90 mmHg on 2 or more&#xD;
                  antihypertensive medications&#xD;
&#xD;
               -  Myocardial infarction within 3 months prior to administration of first dose of&#xD;
                  study drug&#xD;
&#xD;
          -  Subjects with delayed healing of wounds, ulcers, and/or bone fractures&#xD;
&#xD;
          -  Pulmonary hypertension or pneumonitis&#xD;
&#xD;
          -  Serious/active infection; infection requiring parenteral antibiotics&#xD;
&#xD;
          -  Inadequate recovery from any prior surgical procedure; major surgical procedure within&#xD;
             6 weeks prior to study entry&#xD;
&#xD;
          -  Uncontrolled psychiatric disorder, altered mental status precluding informed consent&#xD;
             or necessary testing&#xD;
&#xD;
          -  Inability to comply with protocol requirements&#xD;
&#xD;
          -  Ongoing hemoptysis or history of clinically significant bleeding&#xD;
&#xD;
          -  Cerebrovascular accident within 12 months of study entry, or peripheral vascular&#xD;
             disease with claudication on walking less than 1 block&#xD;
&#xD;
          -  Deep venous thrombosis or pulmonary embolus within 6 months of study entry and/or&#xD;
             ongoing need for full-dose oral or parenteral anticoagulation&#xD;
&#xD;
          -  Subjects with a &quot;currently active&quot; second primary malignancy other than non-melanoma&#xD;
             skin cancers. Subjects are not considered to have a &quot;currently active&quot; malignancy if&#xD;
             they have completed anti-cancer therapy and are considered by their physician to be &lt;&#xD;
             30% risk of relapse.&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Known concomitant genetic or acquired immune suppression disease such as HIV&#xD;
&#xD;
        Prohibited medications:&#xD;
&#xD;
          -  VEGF receptor (VEGFR) targeted therapy within 4 weeks prior to and during study&#xD;
&#xD;
          -  Other signal transduction inhibitors, monoclonal antibodies, etc., within 4 weeks&#xD;
             prior to and during study&#xD;
&#xD;
          -  Immunotherapy or biological response modifiers within 4 weeks prior to and during&#xD;
             study&#xD;
&#xD;
          -  Systemic hormonal therapy within 4 weeks prior to and during study, with the exception&#xD;
             of:&#xD;
&#xD;
               -  Hormonal therapy for appetite stimulation or contraception&#xD;
&#xD;
               -  Nasal, ophthalmic, and topical glucocorticoid preparations&#xD;
&#xD;
               -  Oral replacement therapy for adrenal insufficiency&#xD;
&#xD;
               -  Low-dose maintenance steroid therapy for other conditions&#xD;
&#xD;
          -  Herbal preparations/supplements (except for a daily multivitamin/mineral supplement&#xD;
             not containing herbal components) within 2 weeks prior to or during study&#xD;
&#xD;
          -  Any experimental therapy 4 weeks prior to and during study&#xD;
&#xD;
          -  Radiotherapy:&#xD;
&#xD;
               -  At least 2 weeks since prior local radiation therapy (ie, involving &lt;25% of bone&#xD;
                  marrow) at the time of study entry&#xD;
&#xD;
               -  At least 4 weeks since prior radiation therapy involving ≥ 25% of bone marrow&#xD;
&#xD;
          -  Treatment with CYP3A4 inducers or inhibitors during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Zhang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>AVEO Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>September 30, 2011</last_update_submitted>
  <last_update_submitted_qc>September 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tivozanib</keyword>
  <keyword>AV-951</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

